Journal
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Volume 75, Issue 10, Pages 1196-1207Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2019.12.058
Keywords
biomarkers; cardiac magnetic resonance; cardiopulmonary exercise testing; dilated cardiomyopathy; genetics; nonischemic cardiomyopathy
Categories
Funding
- National Institute for Health Research at the Cardiovascular Research Centre, Glenfield Hospital
- British Heart Foundation at the Cardiovascular Research Centre, Glenfield Hospital
- British Heart Foundation at Imperial College London
- Alexander Janson's Foundation at Imperial College London
- Rosetree's Foundation at Imperial College London
Ask authors/readers for more resources
Dilated cardiomyopathy (DCM) is a common condition, which carries significant mortality from sudden cardiac death and pump failure. Left ventricular ejection fraction has conventionally been used as a risk marker for sudden cardiac death, but has performed poorly in trials. There have been significant advances in the areas of cardiac magnetic resonance imaging and genetics, which are able to provide useful rick prediction in DCM. Biomarkers and cardiopulmonary exercise testing are well validated in the prediction of risk in heart failure; however, they have been tested less specifically in the DCM setting. This review will discuss these methods with a view toward multiparametric risk assessment in DCM with the hope of creating parametric risk models to predict sudden cardiac death and pump failure in the DCM population. (C) 2020 the American College of Cardiology Foundation. Published by Elsevier. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available